Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Budget Peptide Protocol Beginners Under $100/Month: Protocol Comparison

Anabolic/Recovery MK-677 (10mg daily) 300mg $20 MK-677 + $25 Thymalin (amortised quarterly) + $15 bacteriostatic supplies = $60 GH secretagogue (24hr half-life) + immune modulation Best all-around value for researchers prioritising lean mass and recovery—prove

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Anabolic/Recovery
  • MK-677 (10mg daily)
  • 300mg
  • $20 MK-677 + $25 Thymalin (amortised quarterly) + $15 bacteriostatic supplies = $60
  • GH secretagogue (24hr half-life) + immune modulation
  • Best all-around value for researchers prioritising lean mass and recovery—proven endocrine response at one-third the cost of GLP-1 protocols
  • Cognitive/Neuroprotection
  • Dihexa (10mg daily)
  • $25 Dihexa + $50 Cerebrolysin (every 72hr) + $10 supplies = $85
  • HGF upregulation (synaptogenesis) + neurotrophic factor elevation
  • Ideal for cognitive research—mechanism targets structural plasticity, not neurotransmitter flux, making it complementary to racetams
  • Metabolic/Body Composition
  • MK-677 (15mg every 48hr) + KPV
  • 225mg MK-677 + 50mg KPV
  • $30 MK-677 + $40 KPV + $15 supplies = $85
  • GH secretagogue + anti-inflammatory peptide (gut-brain axis modulation)
  • Cost-effective metabolic stack—KPV addresses GI inflammation that can limit nutrient partitioning, synergising with MK-677's anabolic signalling
  • Immune/Longevity
  • Thymalin (10-day course quarterly) + Cartalax
  • 100mg Thymalin + 60mg Cartalax
  • $50 Thymalin + $35 Cartalax (amortised) + $10 supplies = $95
  • Thymic peptide restoration + telomere-protective bioregulator
  • Best for researchers over 35 prioritising immune function and cellular senescence—mechanisms target age-related decline, not acute performance